- Home
- MGRX vs ENVB Comparison
MGRX vs ENVB Comparison
Compare MGRX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | ENVB |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 8.1M |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MGRX | ENVB |
|---|---|---|
| Price | $0.52 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 404.8K | 104.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $456,021.00 | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.56 |
| 52 Week High | $2.75 | $13.25 |
Technical Indicators
Market Signals| Indicator | MGRX | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 37.43 |
| Support Level | $0.52 | $0.57 |
| Resistance Level | $0.56 | $1.54 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 83.96 | 20.56 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.